Orthovita presses on with US kyphoplasty trial:
This article was originally published in Clinica
Orthovita has completed the patient-enrolment phase of its second US pilot study evaluating its Cortoss biomaterial as a treatment for vertebral compression fractures of the spine. The 20-patient, four-centre study is assessing use of the synthetic cortical bone void filler during kyphoplasty. With kyphoplasty, an inflatable bone tamp is used to restore vertebral height and create a void into which the biomaterial can be injected percutaneously to stabilise the fracture and restore load-bearing capability. Another US trial testing Cortoss in spinal fractures is also underway, notes the Malvern, Pennysylvania firm. It is testing use of the biomaterial during vertebroplasty, whereby Cortoss is injected directly into the vertebral body. Cortoss is already approved in Europe for treating vertebral compression fractures.